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A pathologist's role in evaluation of postneoadjuvant chemotherapy epithelial ovarian carcinomas
Editor, Epithelial ovarian carcinomas (EOCs) are aggressive tumors, which often present with advanced stage disease. Hence, such cases have a relatively poorer prognosis and survival rate. The use of neoadjuvant chemotherapy (NACT), followed by tumor reduction surgery, also called as interval debulking surgery, is considered as an alternative therapeutic regimen for selected patients harboring advanced stage EOC. [1] Till date, several studies have attempted to draw an association between NACT and the histology of residual tumor, its grade, stage with the prognosis. A tumor regression grading (TRG) score which is widely used in cancers of gastrointestinal tract, has not been formulated for ovarian carcinomas, till date.
Our aims of this study were to assess the pathological outcome in cases of EOCs, post-NACT and to assess the uniformity of grossing techniques in post-NACT-treated specimens.
All pathology reports of "in-house" operated cases of carcinoma ovary of 1 year duration (January 2011-December 2011) were retrieved from the medical records of our institution. A total of 162 cases of total abdominal hysterectomy with bilateral salpingo-oophorectomy and omentectomy, post-NACT-treated EOC were retrieved.
In 1 year, 162 cases of EOC received NACT. Before the induction of therapy, majority of the patients had undergone ascitic fluid examination (111/162), or a biopsy (29/162) or a fine needle aspiration cytology diagnosis (10/162). The median age-group of these patients was 52 years, the mean being 51.04 years. The following table shows the post-NACT residual tumor status and histological subtyping [ Table 1 ].
Among a total number of cases with residual tumors, serous adenocarcinomas formed the most frequent histopathological subtype (66.67%). Immunohistochemical (IHC) staining was performed in 16/162 cases, to further subtype the tumor (in post-NACT samples). Necrosis, inflammation, psammomatous calcification, foamy histiocytes, hemosiderin laden macrophages, and foreign body type giant cells constituted as therapy-related changes. Ovaries were submitted entirely in 48/162 cases (29.62%). Out of the 146 cases with residual tumor, 11 out of 162 had "complete response" (no residual tumor at the primary or secondary site).
While grossing the specimen of an ovarian tumor wherein NACT was administered, representative sections were given where the presence of tumor was evident on gross examination. Till date, no protocol is followed as to the sampling of ovary in such cases. However, the ovaries in our cases were submitted entirely when the tumor was not visible on gross examination; when size of the ovary was within 4 cm (maximum dimension) and before confirming the microscopic diagnosis of "nonresidual" tumor. This minimized the possibility of error in reporting the residual status of the disease. We also recommend that if residual tumor is seen in only one of the ovaries, the contralateral ovary must be submitted entirely as high-grade serous adenocarcinomas have the propensity to occur bilaterally. A larger study will be undertaken for further validating these observations.
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There are no conflicts of interest. In this study, there were 90.13% of cases which showed residual tumor on histopathology, whereas complete response was seen in 9.87% cases. As per established literature, chemotherapy induces morphological variations in the original tumor, which make it difficult or sometimes impossible to subtype the tumor. However, this should be attempted. [2] Many study results have shown histologic response to be a prognostic indicator. [1] [2] [3] IHC staining was performed in 9% cases to subtype the tumor. Chemotherapy has many effects on the morphology of the tumor. A serous tumor with clear cell change can mimic a clear cell adenocarcinoma. [4] Wilms' tumor 1 (WT-1) may be a useful antibody marker, especially if IHC before NACT has not been performed. Futhermore, normal cells might appear bizarre and could cause confusion as to the presence of residual tumor. In such scenarios, IHC is a useful adjunct.
Optimal cytoreduction has been defined as residual tumor <1 cm. However, the Gynecologic Cancer Interstudy Group has changed this to complete resolution of all tumor. [5] Thus, 100% response or no residual tumor on microscopy is considered as good/complete response to therapy.
Currently, there is no unified TRG of ovarian/tubal/peritoneal high-grade carcinomas that have been treated with NACT. TRG scoring has been applied to cancers of the breast, stomach, esophagus, and colorectum as a prognostic tool. Few investigators evaluated the effect of NACT in advanced-stage EOC, in the form of correlation between response and survival. A recent study suggested applying the TRG score to the omental metastasis stating it to be superior than the one in the primary tumor site. [6] In our study, 5/16 cases which showed a complete response to therapy (no residual viable tumor in the primary ovarian site), also had omental metastasis. Thus, in future, a TRG score assessing the tumor presence at metastatic site as well rather than only the primary could prove more beneficial. The presence of omental metastasis is taken as pathological Stage III. Thus, in this series, 10.4103/0377-4929.191780
Adult T-cell leukemia/lymphoma: Unusual immunophenotype by flow cytometry
Editor, Adult T-cell leukemia/lymphoma (ATLL) is a unique T-cell neoplasm etiologically linked to human T-lymphotropic virus type 1 (HTLV 1). It usually affects adults and has poor prognosis with median survival time of 13 months even if multiagent chemotherapy is given. The immunophenotype of ATLL is that of activated mature T lymphocytes express CD2 and CD5 and are usually CD4+/CD8-. CD3 and T-cell receptor (TCR) αβ may be downregulated and CD7 is negative. The strong expression of alpha chain of the interleukin-2 receptor recognized by monoclonal antibody CD25 is a distinctive feature. [1] A 56-year-old male patient presented with extensive maculopapular skin lesions and tiredness. On investigation, the white blood cell count was 225,000/mm 3 . Platelet count was 80,000/mm 3 . Lactate dehydrogenase (LDH) was 3159 (normal range 313-618 µ/L). Serum calcium level was increased 18.3 (normal range 8.4-10.2 mg/dL). Peripheral blood examination showed 88% atypical cells with scant to moderate amount of cytoplasm, irregular/ multilobated nuclei [ Figure 1 ]. Bone marrow aspiration and biopsy showed atypical lymphoid cells with irregular nuclei infiltrating marrow. Flow cytometric evaluation of peripheral blood showed the atypical cell population to be CD2+, CD3+, CD4-, CD5-, CD7-, CD8-, CD25+, CD56-, CD34-, Tdt-, CD64-, TCR αβ+, and TCR γδ-[ Figure 2 ]. Correlating clinical feature (extensive skin lesions), biochemical parameters (elevated calcium and LDH), cell morphology (cells with irregular/lobated nuclei), and immunoprofile (CD2+, CD3+, CD7-, CD25+, TCR αβ+ Tdt-and CD34-), the diagnosis of ATLL was made even though the CD4-, CD8-, CD5 -immunophenotype is rare in ATLL. Serum HTLV 1 estimation, done by Western blot method, was positive.
ATLL, a peripheral T-cell lymphoma associated with HTLV 1 infection, is an aggressive neoplasm characterized by poor response to chemotherapy and short survival. Because of the diverse clinical features, ATLL is classified into acute, chronic, lymphomatous and smoldering types. [1] ATLL is endemic in southwestern Japan, the Caribbean basin and parts of central Africa. The distribution of ATLL is related to the prevalence of HTLV infection. The diagnosis of ATLL is by positive serology study for anti-HTLV 1 antibody and confirmation by Southern blotting. There are only limited case reports of ATLL from India. The largest series describes 15 cases of serum HTLV 1 positive ATLL from Kerala, South India. [2] T-cells arise from bone marrow precursors which undergo maturation and differentiation in the thymus. The cortical thymocytes have an immature T-cell phenotype and express Tdt, CD1a, CD5, CD7, and cytoplasmic CD3. Medullary T-cells express CD2, surface CD3 and CD7 and are negative for Tdt and CD1a. The immature cortical thymocytes are CD4-and CD8-. Maturing thymocytes coexpress CD4 and CD8. More mature T-cells express either CD4 or CD8. [1] ATLL is associated with HTLV 1 which usually infects CD3+, CD4+, CD25+, HLADR + mature T-cells. A majority of the 
